middle.news
Cambium Bio Advances Phase 3 Trials with Strategic Deals and Fresh Funding
9:52am on Friday 20th of February, 2026 AEDT
•
Healthcare
Read Story
Cambium Bio Advances Phase 3 Trials with Strategic Deals and Fresh Funding
9:52am on Friday 20th of February, 2026 AEDT
Key Points
FDA clearance achieved for Phase 3 patient dosing of Elate Ocular®
Three strategic partnerships established for manufacturing and commercialisation
Half-year loss narrowed to $1.46 million from $1.72 million prior year
Raised A$2.17 million in July 2025 and secured A$2.4 million placement from ZYBT
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cambium Bio (ASX:CMB)
OPEN ARTICLE